A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 1.94 USD -0.51% Market Closed
Market Cap: 70.2m USD
Have any thoughts about
Armata Pharmaceuticals Inc?
Write Note

Armata Pharmaceuticals Inc
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Armata Pharmaceuticals Inc
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Net Income
-$41.4m
CAGR 3-Years
-20%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Income
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
5%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Armata Pharmaceuticals Inc
Glance View

Market Cap
70.2m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
2.18 USD
Undervaluation 11%
Intrinsic Value
Price
A

See Also

What is Armata Pharmaceuticals Inc's Net Income?
Net Income
-41.4m USD

Based on the financial report for Sep 30, 2024, Armata Pharmaceuticals Inc's Net Income amounts to -41.4m USD.

What is Armata Pharmaceuticals Inc's Net Income growth rate?
Net Income CAGR 5Y
-17%

Over the last year, the Net Income growth was 31%. The average annual Net Income growth rates for Armata Pharmaceuticals Inc have been -20% over the past three years , -17% over the past five years .

Back to Top